Please login to the form below

Not currently logged in

Sanofi, Regeneron offer price cut for cholesterol drug Praluent

Amgen’s Repatha also struggled to secure reimbursement at its launch price point

Sanofi reception

Sanofi and Regeneron’s cholesterol-lowering drug Praluent has struggled to make headway in the market, and the companies are now offering a flexible pricing approach to try to encourage healthcare payers to stump up for the drug.

The offer has been made just after the presentation of the large-scale ODYSSEY OUTCOMES at the American College of Cardiology (ACC) meeting in Orlando, which showed that adding PCSK9 inhibitor Praluent (alirocumab) to high-dose statins reduced cardiovascular events and all-cause mortality compared to statins alone.

Armed with that data, as well as new cost-effectiveness analysis from the US Institute for Clinical and Economic Review (ICER) which provide new estimates of the price range that would be acceptable for the drug – depending on the patient’s level of risk.

Both Praluent and Amgen’s rival PCSK9 inhibitor Repatha (evolocumab) were launched a couple of years ago with a list price of around $14,000 a year, and at that price point have struggled to secure reimbursement from healthcare payers in the US. Amgen - which has been locked in litigation with Sanofi and Regeneron over PCSK9 patent rights - reported positive cardiovascular outcomes data for its drug last year when it published the results of the FOURIER trial.

Now, Sanofi and Regeneron have laid down the gauntlet to their rival, saying they will “offer US payers that agree to reduce burdensome access barriers for high-risk patients a further reduced net price for Praluent … in alignment with a new value assessment for high-risk patients”.

ICER’s latest analysis sets a value-based price range of $4,500-8,000 per year, net of rebates and discounts, for this group, and the companies have said they will offer discounts of up to 69% to health insurers that reduce prescribing obstacles and will be meeting with US health plans to discuss pricing adjustments.

“We believe a new paradigm is needed in how all members of the healthcare community collaborate to ensure that patients are able to affordably access the medical treatments they need,” said Regeneron chief executive Leonard Schleifer in a statement.

“We commit to working with all health plans that agree to remove access barriers for high-risk patients to offer a more cost-effective net price for Praluent,” he continued. “We hope that our unprecedented approach to collaborating with payers and other stakeholders demonstrates that it is possible to bring major innovation to patients at a price that aligns with the value delivered.”

Article by
Phil Taylor

12th March 2018

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...